MedPath

JORDAN SCHULTZ

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

2

Active:1
Completed:1

Trial Phases

1 Phases

Phase 1:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (100.0%)

A Pilot Study of Terazosin for Parkinson's Disease

Phase 1
Completed
Conditions
Parkinson Disease
Interventions
Drug: Placebo oral capsule
First Posted Date
2019-04-05
Last Posted Date
2022-05-16
Lead Sponsor
Jordan Schultz
Target Recruit Count
13
Registration Number
NCT03905811
Locations
🇺🇸

University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States

Neurobiological Predictors of Huntington's Disease (PREDICT-HD)

Active, not recruiting
Conditions
Huntington Disease
First Posted Date
2003-01-09
Last Posted Date
2025-01-14
Lead Sponsor
Jordan Schultz
Target Recruit Count
1700
Registration Number
NCT00051324
Locations
🇺🇸

University of Iowa, Iowa City, Iowa, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.